Ovarian Cancer

One patient provides potential caregivers “a guide to help you help me”.

Two-time cancer survivor Anne Weber feels fortunate to have learned of her BRCA2 gene mutation, as it led to an early diagnosis of aggressive breast cancer.

Here is a list of the recent trial initiations that occurred within the cancer space in November.

From the first patient death under the Right to Try law to a 9-year-old ovarian cancer survivor meeting her hero Jim Cantore, here’s what is making headlines in the cancer space this week.

“When learning about a second relapse, the only thing I could think was, ‘Oh no. Not again. This cannot be happening.”

You never expect to get a diagnosis of cancer, but what about when it comes back?

Revised federal guidelines recommend that more women, especially cancer survivors, be considered for genetic screening for hereditary breast and ovarian cancer.

I was never any good at math, but I can count. So I learned to live by this bit of information by counting the days that passed after my treatments for ovarian cancer.

The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.

Looking back on Day One in the chemotherapy journey.

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status.

Before getting genetic testing for hereditary ovarian, breast or other cancers, make sure the company providing it is both reputable and qualified.

"They say once you hear the word cancer, you retain maybe 40 percent of the information that follows, but the words 'ovarian cancer' got through alright."

An ovarian cancer survivor shares what she wishes she had known then with those who are newly diagnosed.

Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer.

"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."

CURE spoke with an expert on how patients can better advocate for themselves when it comes to genetic testing and its follow-up.

Ovarian Cancer Research Alliance (OCRA) supports women and their families going through an ovarian cancer diagnosis, while also funding the research that will one day lead to its prevention.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

CURE spoke with an expert from Mount Sinai to discuss the future of ovarian cancer treatment and his advice for women facing a new diagnosis.

“For so long ovarian cancer has been a secret part of my life. That’s over now.”